Phillips-Medisize Corp. will add to its Menomonie, Wis., campus, with an 80,000-square-foot facility to be used for high volume prefilled drug delivery systems.
The company said in a news release that the investment is driven by the signing of a new supply contract with a major biopharmaceutical company, and is expected to create jobs for more than 100 employees. It is scheduled to be completed in 2017.
“Expanding in Menomonie adds to our manufacturing capacity to produce fully assembled and packaged drug delivery devices. We are proud of this leading edge manufacturing campus featuring advanced molding and assembly, cold-chain drug handling, serialization technologies and [Food and Drug Administration]-registered dedicated clinical and pilot build facilities for drug delivery and finished combination products,” said Matt Jennings CEO and president of Phillips-Medisize in a statement.
Jennings added that the company's recent acquisition by Molex LLC also bolsters its ability to provide end-to-end electronics solutions as part of its drug delivery device capabilities.
Phillips-Medisize, based in Hudson, Wis., continues to build its contract design, development and manufacturing capabilities to serve the drug delivery, consumable diagnostics and medical/surgical markets. It is also collaborating with the University of Wisconsin-Stout, located in Menomonie, to provide technical resources and an educated workforce.
This year has been a busy one for Phillips-Medisize. In October, it was purchased by Molex, a global manufacturer of electronic, electrical and fiber optic systems. In the summer, Phillips-Medisize acquired Medicom Innovation Partner A/S, a Danish company focused on the design and development of connected health drug delivery systems and combination devices.
Also in 2016, it opened a dedicated 17,000-square-foot clinical and pilot building facility for drug delivery and combination devices in Menomonie, and purchased Injectronics Inc., based in Clinton, Mass., to push into the Northeast.
Phillips-Medisize employs over 4,300 in 17 production locations in the U.S., Europe, Mexico and China. It also has a global design network with hubs in Hudson and Stuer, Denmark.
The company was ranked 18th in Plastics News' most recent North American rankings of injection molders with $355.4 million in injection molding sales. Its website said that it had over $700 million in sales with 80 percent coming from drug delivery, medical devices and diagnostic products.